Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirus
Open Access
- 26 March 2018
- journal article
- research article
- Published by Elsevier BV in Virology
- Vol. 518, 324-327
- https://doi.org/10.1016/j.virol.2018.03.015
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health & Welfare, Republic of Korea (HI15C3034, HI15C3227)
This publication has 17 references indexed in Scilit:
- Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune systemClinical and Experimental Immunology, 2016
- Serum Levels of Soluble CD26, A Novel Prognostic Marker for Hepatitis E InfectionJundishapur Journal of Microbiology, 2016
- Dipeptidyl Peptidase 4 Distribution in the Human Respiratory TractThe American Journal of Pathology, 2015
- Middle East Respiratory Syndrome in 3 Persons, South Korea, 2015Emerging Infectious Diseases, 2015
- DPP4 in diabetesFrontiers in Immunology, 2015
- Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 InhibitorsEndocrine Reviews, 2014
- Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2014
- Sputum Autoantibodies in Patients With Established Rheumatoid Arthritis and Subjects at Risk of Future Clinically Apparent DiseaseArthritis & Rheumatism, 2013
- Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMCNature, 2013
- Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IVCritical Reviews in Clinical Laboratory Sciences, 2003